Diversified Trust Co Acquires 23,906 Shares of Medtronic PLC $MDT

Diversified Trust Co grew its stake in shares of Medtronic PLC (NYSE:MDT) by 32.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 96,875 shares of the medical technology company’s stock after acquiring an additional 23,906 shares during the period. Diversified Trust Co’s holdings in Medtronic were worth $9,226,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. 1248 Management LLC purchased a new stake in Medtronic during the 1st quarter worth about $26,000. Delos Wealth Advisors LLC purchased a new position in Medtronic during the 2nd quarter valued at about $27,000. Twin Tree Management LP bought a new stake in shares of Medtronic during the first quarter valued at about $29,000. Tripletail Wealth Management LLC bought a new stake in shares of Medtronic during the third quarter valued at about $34,000. Finally, GFG Capital LLC purchased a new stake in shares of Medtronic in the second quarter worth about $36,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Trading Down 0.5%

NYSE MDT opened at $96.05 on Tuesday. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The stock’s 50-day simple moving average is $97.54 and its two-hundred day simple moving average is $93.86. Medtronic PLC has a twelve month low of $79.29 and a twelve month high of $106.33. The company has a market capitalization of $123.13 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 2.54 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The firm had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 3.0%. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on MDT. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the company a “neutral” rating in a research report on Wednesday, November 19th. Robert W. Baird set a $103.00 price objective on Medtronic in a research report on Tuesday, December 16th. Wells Fargo & Company lifted their price objective on Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Finally, Jefferies Financial Group restated a “hold” rating and set a $110.00 target price on shares of Medtronic in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and an average target price of $109.94.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).